^
Association details:
| Biomarker: | ALK R1275Q |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of Crizotinib in Patients with ALK-aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Published date:
02/10/2021
Excerpt:
The objective response rate for patients with neuroblastoma was 15% (95% CI: 3.3%,34.3%): two with partial responses and 1 with a complete response. All three patients had a somatic ALK Arg1275Gln mutation, the most common ALK hotspot mutation observed in neuroblastoma and the only mutation predicted to be sensitive to ALK inhibition with crizotinib. Two patients had prolonged stable disease (10 and 13 cycles, respectively); both harbored an ALK Arg1275Gln mutation.
DOI:
10.1158/1078-0432.CCR-20-4224
Source:
Title:
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma
Excerpt:
...ability of crizotinib to inhibit proliferation of neuroblastoma cell lines and xenografts expressing mutated or wild-type ALK....Crizotinib inhibited proliferation of cell lines expressing either R1275Q-mutated ALK or amplified wild-type ALK…
DOI:
10.1126/scitranslmed.3002950
